ADMA Biologics (ADMA) Stock Forecast & Price Target

ADMA$13.68+0.44 +3.32%
BiotechnologyValue StockHigh Quality
Compare
Market cap$3.03BEnterprise value$2.56BRevenue (TTM)$512.27MMarket position—

Score

68
Bullish
Value
68
Quality
88
Growth
47

ADMA Biologics, Inc. price target

ADMA
Low$17.00
Average$18.67
High$21.00
Upside vs current price+36.5%

The average target of $18.67 is +36.5% versus the current ADMA price of $13.68.

ADMA Biologics, Inc. analyst ratings

RatingAnalysts
Strong buy1
Buy2
Hold1
Sell0
Strong sell0
ConsensusBuy

4 analysts cover ADMA.

ADMA Biologics, Inc. EPS and revenue estimates

Published annual figures for ADMA on this page are 2026 EPS $0.80, 2027 EPS $0.94. Coverage under three analysts is omitted.

Fiscal yearEPS estimateRevenue estimate
2026$0.80$535.36M
2027$0.94$629.55M

Is ADMA Biologics, Inc. a buy or sell?

Of the 4 analysts covering ADMA Biologics, Inc., 3 rate it a buy (1 strong buy and 2 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The ADMA consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.

The average target of $18.67 implies +36.5% versus the current price of $13.68.

The ADMA rating block is 4 published views with a Buy label. It does not tell you whether to buy or sell.

Reading the ADMA Biologics, Inc. forecast

the ADMA Biologics, Inc. is priced by the street between $17.00 and $21.00, average $18.67.

The gap from the $13.68 price to the ADMA average is +36.5%.

The ADMA rating mix is lopsided rather than split: 3 of 4 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.

the ADMA Biologics, Inc. has a rising EPS path, $0.80 for 2026 and $0.94 for 2027.

With 4 analysts on ADMA, the average is a small sample.

ADMA Biologics, Inc. forecast questions

What is the ADMA price target?

The published range for ADMA is $17.00 to $21.00, with an average of $18.67. That average is +36.5% versus the current price of $13.68.

Is ADMA Biologics, Inc. a buy or sell?

Of the 4 analysts covering ADMA Biologics, Inc., 3 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, leaving ADMA at 3 buy ratings, 1 holds, and 0 sells.

What is the EPS estimate for ADMA Biologics, Inc.?

Analyst EPS estimates for ADMA Biologics, Inc.: 2026 $0.80, 2027 $0.94.

What is the revenue estimate for ADMA Biologics, Inc.?

Analyst revenue estimates for ADMA Biologics, Inc.: 2026 $535.36M, 2027 $629.55M.

How many analysts cover ADMA?

4 analysts cover ADMA. Their consensus on ADMA is Buy, across those 4.

ADMA price $13.68 +0.44 +3.32%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener